A randomised clinical trial investigating the effect of olaparib versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation
Studied treatment | olaparib 300 mg in two 150 mg tablets, twice daily |
Control treatment | placebo |
Patients | patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation |
Group sizes | 196 / 99 |
Blindness | double-blind | Inclusion period | 2013 sept - 201' nov |
Follow-up duration | Centers | multicentre | |
Lost to FU | geographical localisation | international | |
Primary endpoint | investigator-assessed progression-free survival | Design | |
PeriodeInclusion | 2013 sept - 201' nov |
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;: [PMID: 28754483] link to pdf add to Mendeley
ClinicalTrial.gov record NCT01874353
Appears in following systematic reviews: